Health Trials

About this trial

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Eligibility criteria

Qualifiers

Participant ≥ 18 year

ECOG PS of 0 to 1

Provision of 'archival' tumor specimen

At least one measurable lesion according to RECIST v1.1,

Disqualifiers

History or planned organ or allogeneic stem cell transplantation.

Active or prior documented autoimmune or inflammatory disorders, within the past 3 years

Any prior toxicities that led to permanent discontinuation of prior immunotherapy

Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy

Trial design

Treatments tested in this trial

  • AZD6750
  • rilvegostomig

Treatment groups

60 Participants
are divided into 2 treatment groups

Locations

13
Australia
Research Site3002, East Melbourne Australia
Japan
Research Site104-0045, Chūōku Japan
Research Site227-8577, Kashiwa Japan
South Korea
Research Site03080, Seoul South Korea

Sponsors and collaborators

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov